PARP1 and ovarian cancer: Platinum sensitivity serves as a functional biomarker guiding PARP inhibitor clinical application, as PARP inhibitor monotherapy demonstrates limited efficacy in platinum-resistant ovarian cancer (Audeh et al., 2010; Fong et al., 2010; Tew et al., 2020).